BBIO (NASDAQ: BBIO) trust sells repeated 20,000-share blocks under 10b5-1
A Form 144 filing indicates that trusts associated with Kumar Haldea have been consistently selling 20,000-share blocks of BridgeBio Pharma (NASDAQ: BBIO) common stock under 10b5-1 plans. These transactions, reported through Morgan Stanley Smith Barney LLC, occurred on various dates in March, April, and May 2026, with significant aggregate dollar proceeds per sale. The filing also notes a restricted stock unit entry, although it specifies this is a notice of proposed sale rather than a confirmation of holdings or settlement amounts.
BridgeBio’s SWOT analysis: rare disease stock eyes profitability
BridgeBio Pharma (NASDAQ:BBIO) is transitioning to a profitable commercial operation driven by the strong performance of its lead product, Attruby, which exceeded revenue expectations. The company also boasts a robust pipeline of rare disease treatments, with several products targeting billion-dollar opportunities anticipated to launch by 2027. Despite patent uncertainties and negative EPS projections through 2027, analysts forecast BridgeBio to achieve over $600 million in profitability by 2028, contingent on successful execution of commercial momentum and pipeline approvals.
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cullinan Management (CGEM)
J.P. Morgan initiated coverage on BridgeBio Pharma (BBIO) with a Hold rating and an $82.00 price target, while the analyst consensus for BBIO remains a Strong Buy with a $107.41 average target. TD Cowen maintained a Buy rating on Cullinan Management (CGEM), which also has a Strong Buy consensus and an average price target of $31.78. These reports highlight recent analyst activity in the healthcare sector for both companies.
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing
An insider at Bridgebio Pharma sold shares valued at $671,456, as disclosed in a recent SEC filing. This transaction indicates a significant insider sale for the company.
BBIO Stock Price Prediction 2025-2026 | BridgeBio Pharma Inc Forecast
24/7 Wall St. rates BridgeBio Pharma Inc (BBIO) as a BUY, setting a 12-month target price of $117.78, which suggests a 78.46% upside from the current price of $66.00. Optimistic and conservative scenarios project the stock could reach $130.69 or $91.02 respectively, with 96% of analysts also rating it a Buy. Long-term projections for 2031 anticipate a target price around $319.44, indicating significant potential returns.
Bridgebio Pharma Insider Sold Shares Worth $671,456, According to a Recent SEC Filing
An insider at Bridgebio Pharma sold shares valued at $671,456, as reported in a recent SEC filing. The company, a biopharmaceutical firm specializing in genetic diseases, is actively developing various treatments, including those for cardiomyopathy, achondroplasia, and muscular dystrophy. This transaction comes amidst other recent company news, such as a New Drug Application submission and Q1 2026 earnings results.
BridgeBio Pharma (BBIO) CEO reports RSU vesting and tax withholding share disposition
BridgeBio Pharma CEO Neil Kumar reported the vesting of 71,215 Restricted Stock Units (RSUs) on May 16, 2026. To satisfy tax obligations, 36,236 shares were disposed of at $66.13 per share, which was not an open-market sale. Following these transactions, Kumar directly holds 269,430 common shares and has indirect interests through two family trusts, disclaiming beneficial ownership beyond pecuniary interest.
[Form 4] BridgeBio Pharma, Inc. Insider Trading Activity
BridgeBio Pharma, Inc.'s President and CFO, Thomas Trimarchi, engaged in routine insider trading activities according to a recently filed Form 4. On May 18, 2026, he sold 13,651 shares of common stock in the open market, totaling approximately $888,419, under a pre-arranged 10b5-1 sales plan. Additionally, on May 16, 2026, 22,781 shares were withheld to cover taxes related to the vesting of 41,193 Restricted Stock Units (RSUs). Following these transactions, Trimarchi directly holds 359,194 shares of BridgeBio common stock.
BridgeBio Pharma (BBIO) director exercises options and sells 10,000 shares
BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares at $16.75 per share and subsequently sold those 10,000 shares in open-market transactions on May 15, 2026. The sales occurred at weighted average prices between $66.69 and $69.12 per share, under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, the director holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
[144] BridgeBio Pharma, Inc. SEC Filing
This article details a Form 144 SEC filing by BridgeBio Pharma, Inc. (BBIO), indicating a proposed sale of securities. The filing specifies the securities to be sold, their acquisition details, and confirms no prior sales in the last three months by the filer. It also includes the company's recent news and SEC filings.
Janus Henderson (BBIO) discloses 13,179,013 shares, 6.8% ownership
Janus Henderson Group plc has filed an amended Schedule 13G, disclosing beneficial ownership of 13,179,013 shares of BridgeBio Pharma, Inc. (BBIO) Common Stock, which constitutes 6.8% of the class as of March 31, 2026. The filing clarifies that Janus Henderson's Asset Managers exercise shared voting and dispositive power over these shares, held in managed client accounts, and disclaims rights to dividends or sale proceeds for these accounts.
BridgeBio gains amid report of settlement in Pfizer Vyndamax patent dispute
BridgeBio Pharma's stock has risen following a report that the company has settled a patent dispute with Pfizer concerning its drug Vyndapt and Pfizer's Vyndamax. The terms of the settlement were not disclosed but suggest a positive outcome for BridgeBio, which has been developing acoramidis as a potential competitor. This resolution could clear a path for BridgeBio's drug development and market strategy.
Encaleret NDA, Acoramidis Progress, and Buyback Could Be A Game Changer For BridgeBio (BBIO)
BridgeBio Pharma (BBIO) recently announced significant clinical and regulatory advancements, including an FDA submission for encaleret in ADH1 and further Phase 3 data for acoramidis, alongside increased quarterly revenue and a new $500 million share repurchase program. The encaleret NDA specifically aims to diversify BridgeBio's revenue streams and reduce its reliance on Attruby, although the company still faces risks from high R&D spending and potential future dilution. Despite strong clinical data, investors should be aware of persistent losses that could necessitate future equity raises.
Analysts Are Bullish on These Healthcare Stocks: BridgeBio Pharma (BBIO), Palisade Bio (PALI)
Healthcare sector analysts are bullish on BridgeBio Pharma (BBIO) and Palisade Bio (PALI). BridgeBio Pharma received a reiterated Buy rating with a $101.00 price target from Bank of America Securities, and Palisade Bio also secured a reiterated Buy rating with a $7.00 price target from H.C. Wainwright. Additionally, Coya Therapeutics, Inc. (COYA) received a reiterated Buy rating and an $18.00 price target from H.C. Wainwright.
BridgeBio Pharma stock (US10806X1028): Pipeline progress in rare diseases
BridgeBio Pharma is advancing its pipeline focusing on rare genetic disorders and cancers, including significant progress in its TTR amyloidosis program. The company leverages a platform approach through subsidiaries and has over 30 programs in clinical and preclinical stages, with revenue driven by pipeline milestones and partnerships. Investors are closely watching upcoming data readouts and collaborations, positioning BridgeBio as a key player in precision biotech for high-growth rare disease therapies.
BridgeBio’s Encaleret Filing Highlights Next Phase Of Rare Disease Story
BridgeBio Pharma has submitted a New Drug Application to the FDA for encaleret, a drug for autosomal dominant hypocalcemia type 1, following positive Phase 3 trial results. This expands BridgeBio's rare disease pipeline beyond its existing focus and marks a significant step towards commercializing multiple targeted therapies. Investors are now watching the FDA review outcome, planned EU submission, and the balance between capital raising efforts and potential dilution against the backdrop of the company's net losses.
Analysts Offer Insights on Healthcare Companies: Immunic (IMUX) and BridgeBio Pharma (BBIO)
LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunic (IMUX) with a price target of $56.00, noting the company has a Strong Buy consensus among analysts. Wells Fargo analyst Derek Archila reiterated a Buy rating on BridgeBio Pharma (BBIO) with a price target of $98.00, also reflecting a Strong Buy consensus. Both companies show significant upside potential based on current analyst price targets.
BridgeBio Files FDA NDA for Encaleret in ADH1
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) following successful Phase 3 trial results. The drug demonstrated rapid and sustained normalization of calcium metabolism in patients and a favorable safety profile. With a "Buy" rating from analysts and a $101.00 price target, encaleret is poised to be the first approved therapy for ADH1, with potential for expansion into pediatric ADH1 and chronic hypoparathyroidism.
BridgeBio (NASDAQ: BBIO) files NDA as encaleret hits Phase 3 goals in ADH1
BridgeBio Pharma (NASDAQ: BBIO) has submitted a New Drug Application (NDA) to the FDA for encaleret to treat autosomal dominant hypocalcemia type 1 (ADH1) after its Phase 3 CALIBRATE trial met all primary and key secondary efficacy endpoints. The company anticipates a potential U.S. launch in early 2027 and plans further regulatory submissions in Europe and additional clinical studies for pediatric ADH1 and chronic hypoparathyroidism. Encaleret has Fast Track and Orphan Drug designations, highlighting its potential as the first approved therapy for ADH1.
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
Evercore ISI has maintained an "Outperform" rating on BridgeBio Pharma, Inc. (BBIO) and increased its price target to $130 from $125. This decision follows BridgeBio Pharma's strong first-quarter 2026 results, which showed $194.5 million in total revenue, driven by robust sales of Attruby and significant pipeline advancements. The company also announced a $500 million share repurchase program.
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
Evercore ISI has maintained an “Outperform” rating on BridgeBio Pharma, Inc. (BBIO) and increased its price target to $130 from $125. This follows BridgeBio Pharma reporting strong first-quarter 2026 results, with $194.5 million in total revenue driven by Attruby sales. The company also announced ongoing pipeline activity, including NDA submissions and significant cash reserves.
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches
BridgeBio Pharma executives expressed strong confidence in Attruby's commercial trajectory, projecting it will achieve global blockbuster status this year and reach $4 billion in peak U.S. sales. The company also announced plans for three new product launches from its late-stage pipeline, including treatments for limb-girdle muscular dystrophy Type 2I, ADH1 and chronic hypoparathyroidism, and achondroplasia. BridgeBio anticipates over $8 billion in de-risked peak-year sales from Attruby and these three upcoming products, emphasizing their strong clinical data and market potential.
BridgeBio Pharma, Inc. (BBIO) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow
BridgeBio Pharma, Inc. (BBIO) presented at the Bank of America Global Healthcare Conference 2026. The company's Q1 2026 earnings showed an EPS of -$0.84, missing estimates, while revenue of $194.52M beat estimates, representing a 66.78% year-over-year increase. The article highlights the public release of the slide deck from this event.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently purchased between $1,001 and $15,000 worth of BridgeBio Pharma, Inc. (NASDAQ:BBIO) stock on April 29th, according to a May 8th filing. This insider buying comes amidst mixed sentiment for the biotech company, which recently reported Q1 revenue of $194.52 million, beating estimates, despite an EPS miss and a notable share sale by its CEO. Analysts, however, maintain a "Moderate Buy" rating with a consensus target of $88.19 for BBIO.
BridgeBio Submits NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1
BridgeBio has submitted a New Drug Application (NDA) to the FDA for encaleret, a potential first-in-class treatment for autosomal dominant hypocalcemia type 1 (ADH1). This submission follows positive results from the CALIBRATE Phase 3 trial, where encaleret successfully achieved its primary and key secondary endpoints by restoring normal calcium regulation and reducing renal complications. The company anticipates a US launch in early 2027 and is also enrolling pediatric patients in a registrational Phase 2/3 study.
BridgeBio (BBIO) Positioned for Growth According to JPMorgan Analysis
JPMorgan identified BridgeBio Pharma Inc (BBIO) as a prime investment opportunity despite a recent 4% stock decline, projecting an upward trajectory to $90-$100 due to Attruby's strong launch and a robust late-stage pipeline. The company focuses on genetic diseases with a $12.87 billion market cap, but its high P/S ratio, low financial strength, and significant insider selling over the past three months (totaling $27.5 million) suggest caution for investors. While growth potential is strong, financial weaknesses and lack of insider purchases indicate potential underlying issues.
Rare calcium disorder treatment encaleret heads to FDA review
BridgeBio Pharma has submitted a New Drug Application (NDA) to the FDA for encaleret, a potential treatment for autosomal dominant hypocalcemia type 1 (ADH1). The submission is supported by positive Phase 3 CALIBRATE trial results, showing 76% of patients on encaleret achieved target calcium levels compared to 4% on conventional therapy. BridgeBio anticipates a U.S. launch in early 2027 if approved, and plans for EMA submission and further studies in pediatric ADH1 and chronic hypoparathyroidism.
BridgeBio Pharma CEO Neil Kumar sells $5.39m in company stock By Investing.com
BridgeBio Pharma CEO Neil Kumar sold approximately $5.39 million worth of company stock through a pre-arranged sales plan. This sale, executed via family trusts, comes after a significant 97% return in BridgeBio shares over the past year. Analysts have raised price targets for BridgeBio following strong Q1 2026 revenue and promising Phase 3 study data for acoramidis.
Trusts tied to BridgeBio (NASDAQ: BBIO) CEO sell 80K company shares
Trusts associated with BridgeBio Pharma, Inc. CEO Neil Kumar sold a total of 80,000 shares of common stock on May 7-8, 2026. The sales were executed in open-market transactions at prices between approximately $66 and $69 per share, under a pre-arranged Rule 10b5-1 sales plan adopted in March 2025. Following these transactions, Kumar retains significant direct and indirect holdings in the company.
Acoramidis for ATTR-CM reduces hospital stays and worsening heart failure
BridgeBio Pharma reported new Phase 3 data for acoramidis showing significant benefits in patients with ATTR-CM. The drug reduced serum transthyretin (sTTR) variability, which is linked to lower all-cause mortality, and decreased outpatient worsening heart failure risk by 41%. Additionally, acoramidis led to a 34% reduction in cardiovascular hospitalizations compared to tafamidis in an indirect comparison.
BridgeBio Pharma (BBIO): Leveraging Attruby® Revenue to Fuel a Rare Disease Pipeline Targeting Breakthroughs in ADH1 and Achondroplasia
BridgeBio Pharma (BBIO) is transitioning into a high-margin specialty pharmaceutical leader, driven by the successful global launch of its flagship therapy, acoramidis, and strategic pipeline advancements in rare diseases like ADH1 and achondroplasia. The company's "Venture-Pharma" model and robust commercial execution have allowed it to achieve multi-billion-dollar commercial status with strong liquidity, despite competitive pressures. BridgeBio's fair value is estimated at $97.60, reflecting its commercial engine and multi-asset rare disease moat.
BridgeBio Pharma (BBIO) Q4 Revenue Surge Tests Bullish Growth Narratives Against Ongoing Losses
BridgeBio Pharma (BBIO) reported a Q4 revenue of US$154.2 million, contributing to a trailing 12-month revenue of US$502.1 million. Despite this significant revenue growth, the company continues to incur substantial losses, with a basic EPS loss of US$0.99 for Q4 and a net loss of US$724.9 million for the trailing 12 months. This financial performance creates a tension between the bullish outlook based on high revenue forecasts and the concerns raised by ongoing losses, negative shareholder equity, and a premium valuation.
BridgeBio Pharma Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing
BridgeBio Pharma Inc. has filed for a mixed shelf, with the size not disclosed in the SEC filing. This information was reported by Refinitiv and indicates that the company plans to potentially issue various types of securities in the future.
BridgeBio Expects Continued Strength from Attruby
BridgeBio expects continued strong performance from its drug Attruby following its first quarter earnings report on May 7, 2026. The article highlights this information from the company's financial disclosure.
BridgeBio Expects Continued Strength from Attruby
BridgeBio Pharmaceuticals reported its first-quarter earnings on May 7, 2026. The company anticipates continued strong performance from its drug Attruby. This news comes amidst discussions of commercial strategies and research & development within the biopharma industry.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. announced equity grants to 52 new employees, totaling 115,007 restricted stock units. These grants are an inducement for employment, vesting over time, and comply with Nasdaq Listing Rule 5635(c)(4). The company focuses on developing medicines for genetic conditions.
52 new hires get BridgeBio stock awards covering 115,007 shares
BridgeBio Pharma (Nasdaq: BBIO) announced that its compensation committee approved inducement equity grants for 52 new employees, totaling 115,007 restricted stock units. These awards were granted under Nasdaq Listing Rule 5635(c)(4), with a vesting schedule tied to continued employment, starting May 16, 2027. The grants align with the company's existing equity plan, highlighting its use of equity compensation and ongoing hiring efforts.
BridgeBio Pharma Launches New $500 Million ATM Program
BridgeBio Pharma has established a new "at-the-market" (ATM) program, allowing it to sell up to $500 million in common stock through Goldman Sachs & Co. LLC and Leerink Partners LLC. This new agreement replaces a previous one from 2023, providing BridgeBio with a flexible way to raise capital. Despite the company's financial struggles, an AI analyst notes positive outlooks due to strong commercialization efforts, pipeline successes, and improving cash dynamics.
BridgeBio Pharma (NASDAQ: BBIO) launches $500M at-the-market stock program
BridgeBio Pharma has launched a new at-the-market (ATM) stock offering program, allowing it to sell up to $500 million in common stock through Goldman Sachs & Co. LLC and Leerink Partners LLC. This new agreement replaces a prior one from May 2023, effective May 7, 2026. The sales agents will receive a commission of up to 3.0% of the gross proceeds from shares sold.
BridgeBio Pharma (NASDAQ: BBIO) plans $500M ATM common stock offering
BridgeBio Pharma (NASDAQ: BBIO) has filed a shelf registration to offer up to $500 million in common stock through an at-the-market (ATM) offering agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC. The shares may be sold from time to time via at-the-market transactions, block trades, or negotiated sales. Proceeds from this offering are earmarked for general corporate purposes, including R&D, commercialization of Attruby, working capital, and potential investments.
BridgeBio Pharma Inc files for mixed shelf size not disclosed - SEC filing
BridgeBio Pharma Inc. has filed with the SEC for a mixed shelf offering, according to a recent filing. The size of the offering was not disclosed. This news comes amidst other recent announcements from BridgeBio Pharma, including reports on inducement grants, Q1 2026 earnings, and a share buyback plan.
BridgeBio Pharma: Q1 Earnings Snapshot
BridgeBio Pharma Inc. reported a first-quarter loss of $164 million, or 84 cents per share, which missed Wall Street estimates of a 70-cent loss. Despite this, the rare disease drug developer's revenue of $194.5 million exceeded forecasts. The company's shares have decreased by 12% year-to-date, though they have climbed 89% over the past 12 months.
BridgeBio (BBIO) Secures Approval for Beyonttra in Brazil
BridgeBio Pharma Inc (BBIO) has received approval from Brazil's health regulatory agency, ANVISA, to market its drug acoramidis, branded as Beyonttra, for the treatment of transthyretin amyloidosis (ATTR) cardiomyopathy in adult patients. This approval is a significant development for patients in Brazil who have limited treatment options for this severe heart condition. Despite this clinical success, investors are advised to exercise caution due to the company's weak financial strength, high valuation with a price-to-sales ratio of 24.8, and significant insider selling activity totaling $27.9 million over the past three months.
BridgeBio Pharma Announces $500 Million Stock Repurchase Program
BridgeBio Pharma (BBIO) announced a new $500 million stock repurchase program following strong Q1 2026 revenue of $194.5 million, significantly driven by Attruby sales. The company also reported a robust cash position of $940.2 million and is advancing several late-stage rare-disease programs towards potential U.S. launches. Although an AI analyst flagged weak current financials, the company's pipeline progress indicates improving fundamentals.
BridgeBio (NASDAQ: BBIO) surges to $194.5M Q1 revenue and okays $500M buyback
BridgeBio Pharma reported a strong increase in Q1 2026 revenue, reaching $194.5 million, largely driven by sales of its drug Attruby and higher royalties. While the company remained unprofitable with a net loss of $166.6 million, it authorized a $500 million stock repurchase program, signaling confidence in its future. BridgeBio also highlighted key pipeline advancements, including NDA submissions for BBP-418 and planned filings for encaleret and infigratinib.
Earnings Flash (BBIO) BridgeBio Pharma, Inc. Reports Q1 Revenue $194.5M, vs. FactSet Est of $178.6M
BridgeBio Pharma, Inc. (BBIO) announced reported Q1 revenue of $194.5 million, surpassing FactSet's estimate of $178.6 million. The company, a biopharmaceutical firm focused on genetic diseases, also reported a narrowing Q1 loss. This news was published on May 7, 2026.
BridgeBio (NASDAQ: BBIO) Q1 2026 revenue climbs to $194.5M
BridgeBio Pharma Inc. (NASDAQ: BBIO) reported a significant increase in Q1 2026 revenue, reaching $194.5 million, primarily driven by strong sales of Attruby and Beyonttra. Despite this growth, the company recorded a net loss of $164.0 million as it continues to invest heavily in R&D and commercialization efforts. BridgeBio also secured $632.5 million via new convertible senior notes and is actively advancing late-stage product candidates like BBP-418 for LGMD2I/R9.
With $940.2M cash, BridgeBio authorizes a $500M stock buyback
BridgeBio Pharma reported strong Q1 2026 financial results, with total revenues reaching $194.5 million, significantly driven by $180.6 million in U.S. Attruby net product revenue. The company also announced a robust cash position of $940.2 million and authorized a $500 million share repurchase program. Additionally, BridgeBio provided positive updates on its pipeline, including NDA submissions and planned launches for several key therapies addressing genetic conditions.
How Brazil’s BEYONTTRA Approval and New Data Releases Will Impact BridgeBio Pharma (BBIO) Investors
BridgeBio Pharma (BBIO) recently secured Brazilian approval for BEYONTTRA (acoramidis) to treat ATTR-CM, with commercialization slated for H2 2026, expanding its market reach. This development, alongside upcoming Phase 3 data presentations for acoramidis and encaleret, supports the company's rare disease investment narrative. However, investors are cautioned to monitor high operating expenses and potential future equity raises, which remain key risks despite clinical and regulatory progress.
BridgeBio executives set three investor conference appearances
BridgeBio Pharma (BBIO) announced its management will participate in fireside chats at three healthcare investor conferences in May and June 2026. These include the BofA Health Care Conference, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. Live webcasts and replays will be available on the company's investor relations page for 90 days following each event.
